MedTrace Logo

Labor Induction in Preeclampsia High-risk Women

NCT05056467 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 825

Last updated 2023-05-19

No results posted yet for this study

Summary

Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring an increased risk of immediate and long-term health problems. The study team is conducting a study entitled "FORECAST" (Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial) and established the infrastructure for the first-trimester "screen and prevent" program for preterm PE. However, there is no established evidence regarding the benefit of scheduled labor induction versus expectant management among women identified as high-risk for PE with uncomplicated pregnancy at term. The investigators postulate that induction of labor at 39 weeks' gestation may possibly be an effective intervention to reduce placental complications in women with uncomplicated pregnancy by 39 weeks at high-risk PE women.

Conditions

  • Pre-Eclampsia
  • Induction of Labor

Interventions

PROCEDURE

Induction of Labor

Induction of Labor at 39 weeks of gestation

Sponsors & Collaborators

  • Hanoi Obstetrics and Gynecology Hospital

    collaborator OTHER

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Angel Women and Children Hospital

    collaborator UNKNOWN

  • Rumah Sakit Anak dan Bunda Harapan Kita

    collaborator UNKNOWN

  • National University Hospital, Singapore

    collaborator OTHER

  • Taiji Clinic, Taiwan

    collaborator UNKNOWN

  • Siriraj Hospital

    collaborator OTHER

  • Chinese University of Hong Kong

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-08-30
Completion
2024-12-31

Countries

  • China
  • Hong Kong
  • Indonesia
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056467 on ClinicalTrials.gov